By the way, it's also time to name the drug
Immuron Limited is today pleased to announce the topline results of its IMM-124E phase II Non-Alcoholic Steatohepatitis (NASH) clinical study. The results show that Immuron’s oral IMM-124E shows improvement in liver injury and significantly reduces blood levels of LPS (lipopolysaccharide), a known mediator of liver inflammation in patients with NASH. The discovery could have far-reaching opportunities for the effective treatment of a broad range of diseases relating to LPS inflammation beyond NASH.
The clinical study results show;
- First-in class anti-LPS mechanism of action confirmed for IMM-124E.
- Excellent safety and tolerability.
- Statistically significant reduction in serum endotoxin/lipopolysaccharide (LPS) levels compared to placebo.
- Statistically significant reduction in mean serum ALT in patients with elevated pre-treatment ALT
- Statistically significant reduction of additional serum NASH biomarkers associated with liver damage –AST and CK-18.
- IMM-124E retained within the GI tract and not absorbed into the bloodstream, contributing to favourable safety profile.
- Anti-LPS mechanism of IMM-124E may have wider therapeutic applications beyond NASH.
- Forums
- ASX - By Stock
- Reminder of What We Have in IMM-124E
By the way, it's also time to name the drug :):) Immuron Limited...
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMC (ASX) to my watchlist
|
|||||
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $23.93M |
Open | High | Low | Value | Volume |
10.5¢ | 10.5¢ | 10.5¢ | $1.158K | 11.03K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1733 | 10.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
11.0¢ | 127271 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1733 | 0.105 |
6 | 447605 | 0.100 |
1 | 52520 | 0.095 |
1 | 1000 | 0.094 |
1 | 1000 | 0.093 |
Price($) | Vol. | No. |
---|---|---|
0.110 | 127271 | 4 |
0.115 | 100000 | 2 |
0.120 | 193000 | 3 |
0.130 | 218736 | 6 |
0.140 | 105750 | 2 |
Last trade - 10.48am 27/08/2024 (20 minute delay) ? |
Featured News
IMC (ASX) Chart |
The Watchlist
SBW
SHEKEL BRAINWEIGH LTD
Dani Nadri, Country Manager Australia
Dani Nadri
Country Manager Australia
SPONSORED BY The Market Online